15 completed. 15 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 15 |
| Phase 2 | 2 | Completed 2 |
Follow Enterobacteriaceae Infections: new trials by email Literature Review of Enterobacteriaceae Infections trials Research Report on Enterobacteriaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever | Phase 2 / Phase 3 | Completed | EuBiologics Co.,Ltd | 444 | 2020-09-07 | 2021-10-07 |
| Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague Ciprofloxacin, Streptomycin, Gentamicin - Plague, Bubonic, Plague, Pneumonic | Phase 3 | Completed | University of Oxford | 222 | 2020-02-15 | 2025-03-06 |
| Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid | Phase 3 | Completed | International Vaccine Institute | 1800 | 2020-02-04 | 2021-08-27 |
| Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae Antipseudomonal beta-lactam antibiotic, De-escalation(short-spectrum antibiotic) - Enterobacteriaceae Infections | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 344 | 2016-10-01 | 2020-07-17 |
| Nepal Undifferentiated Febrile Illness Trial Azithromycin, Co-trimoxazole - Undifferentiated Febrile Illness | Phase 3 | Completed | Oxford University Clinical Research Unit, Vietnam | 330 | 2016-05-23 | 2023-12-06 |
| Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae 7 days course of antibiotic treatment, 14 days course of antibiotic treatment - Enterobacteriaceae Infections, Bloodstream Infection | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 238 | 2014-09-01 | 2017-03-13 |
| Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli Fosfomycin sodium intravenous, Meropenem intravenous, Ceftriaxone intravenous - Infection Due to ESBL Escherichia Coli | Phase 3 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 161 | 2014-07-01 | 2019-08-06 |
| Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects Typhoid Vi polysaccharide - Salmonella Infections, Typhoid Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 200 | 2012-05-01 | 2014-05-12 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S. Rifaximin - Diarrhea | Phase 3 | Completed | Bausch Health Americas, Inc. | 660 | 2005-12-01 | 2019-11-25 |
| Rifaximin for Prevention of Travellers' Diarrhea Rifaximin, Placebo - Diarrhea | Phase 3 | Completed | Bausch Health Americas, Inc. | 210 | 2005-06-01 | 2019-12-18 |
| Treatment and Diagnosis of Plague gentamicin, streptomycin - Plague | Phase 2 / Phase 3 | Completed | Centers for Disease Control and Prevention | 114 | 2004-08-01 | 2009-02-26 |
| Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Shigella conjugate vaccines - Shigellosis | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2799 | 2003-01-01 | 2012-06-22 |
| Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix - Hepatitis A | Phase 3 | Completed | GlaxoSmithKline | 1034 | 2002-05-01 | 2016-09-09 |
| Zinc Supplementation in Shigella Patients Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks. - Testing Effect of Intervention | Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 56 | 1999-01-01 | 2006-05-03 |
Typhoid Fever (6) · Bacteremia (3) · Dysentery, Bacillary (3) · Escherichia coli Infections (3) · Recurrence (3) · Sepsis (3) · Diarrhea (2) · Plague (2) · Bacterial Infections (1) · Dysentery (1) · Encephalitis, Japanese (1) · Hepatitis A (1) · Meningitis, Meningococcal (1) · Meningococcal Infections (1)
Bacterial Infections and Mycoses (15) · Gram-Negative Bacterial Infections (15) · Infections (15) · Bacterial Infections (14) · Pathological Conditions, Signs and Symptoms (5) · Salmonella Infections (5) · Digestive System Diseases (4) · Disease Attributes (3) · Gastroenteritis (3) · Gastrointestinal Diseases (3) · Inflammation (3) · Intestinal Diseases (3) · Pathologic Processes (3) · Systemic Inflammatory Response Syndrome (3)
Ciprofloxacin (2) · Gentamicins (2) · Rifaximin (2) · Streptomycin (2) · Trimethoprim, Sulfamethoxazole Drug Combination (2) · Vi polysaccharide vaccine, typhoid (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Ampicillin (1) · Anti-Bacterial Agents (1) · Azithromycin (1) · Aztreonam (1) · Cefepime (1) · Ceftazidime (1) · Cefuroxime (1) · Diphtheria Toxoid (1)
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (3) · Bausch Health Americas, Inc. (2) · Centers for Disease Control and Prevention (1) · EuBiologics Co.,Ltd (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GlaxoSmithKline (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · International Vaccine Institute (1) · Novartis (1) · Oxford University Clinical Research Unit, Vietnam (1) · Sanofi Pasteur, a Sanofi Company (1) · University of Oxford (1)
Spain (3) · Madagascar (2) · Philippines (2) · Czechia (1) · Germany (1) · Israel (1) · Japan (1) · Mexico (1) · Nepal (1) · United States (1)
Buddha Basnyat, MBBS,MSc,MD (1) · Jose Molina Gil-Bermejo, MD. PhD (1) · Josefina C Carlos, MD (1) · Kevin Griffith, MD, MPH (1) · Luis Eduardo Lopez Cortes, MD, PhD (1) · Martin Schriefer, PhD (1) · Peter W Horby, MD (1) · Rachel Schneerson, MD (1) · Swapan Kumar Roy, MBBS, M.Sc, Ph. D (1)
PMID 17554249, PMID 20056180, PMID 20412178, PMID 24873986, PMID 25308927, PMID 25829373, PMID 28601833, PMID 28969659, PMID 32807214, PMID 32991678, PMID 35024838, PMID 35664443, PMID 36774331, PMID 38215770, PMID 38970065, PMID 40768716